Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
NervGen reported Q2 2026 financial results and business updates, highlighting the upcoming start of site activation and participant screening for its pivotal Phase 3 RESTORE clinical trial targeting chronic spinal cord injury with NVG-291. The company enhanced its leadership team and secured $61.1 million USD in cash, affirming funding sufficiency …
Abeona Therapeutics reported strong Q2 2026 financial results highlighted by a 31% sequential increase in net revenue from their gene therapy product ZEVASKYN to $11.4 million. The company expanded its qualified treatment center (QTC) network nationwide and secured New Technology Add-On Payment (NTAP) status from CMS, facilitating Medicare reimburs…
Cabaletta Bio reported Q2 2026 financial results and updated progress on its lead CAR T cell therapy, rese-cel, designed to treat autoimmune diseases. Key milestones include on-track registrational RESET-Myositis data expected mid-2027 to support a 2H27 BLA submission, initiation of registrational RESET-SSc study in Q4 2026, and expansion of PC-fre…
MiNK Therapeutics reported second quarter 2026 financial results and clinical progress on its lead product, agenT-797, which is an off-the-shelf allogeneic invariant natural killer T cell therapy. The company initiated dosing in a randomized Phase 2 clinical trial (C-1300-02) for acute lung injury and ARDS in Ukraine, achieving Day 28 survival and …
FitLife Brands, Inc. reported a 65% increase in total revenue to $26.5 million in Q2 2026, driven primarily by the acquisition of Irwin Naturals. Wholesale revenue surged 156%, with Irwin contributing $10.7 million. Despite a decline in Legacy FitLife revenue, overall net income rose 12% to $2.0 million and adjusted EBITDA was up 10%. The company r…
Cerenome, Inc., a U.S. CNS oncology company, announced a significant in-network agreement with Health Care Service Corporation (HCSC) to provide its CNSide® cerebrospinal fluid tumor cell enumeration assay. This expands Cerenome's contracted commercial and Medicare Advantage coverage to over 153 million covered lives, surpassing their 2026 year-end…
UTStarcom Holdings Corp. announced a change in its finance leadership. CFO Dan Xie will step down from his role effective August 21, 2026, moving to Vice President overseeing India and Japan operations. Ying Kang joins as Assistant Vice President of Finance and will take full control of the finance department starting August 21, 2026. The changes w…
The Antwerp World Diamond Centre (AWDC) has denied any connection between a luxury ring presented as a diplomatic gift and a subsequent U.S. tariff exemption for European natural diamonds, after two Democratic senators sought answers and warned of possible legal issues under U.S. federal bribery law.
Meta’s Family of Apps continues to generate robust cash flow and attractive returns on equity, trading at a mid-20s P/E while producing roughly $41B of free cash flow. The main risk is elevated capex and spending cadence tied to AI infrastructure and Reality Labs. This trade aims to capture upside from a slower-than-feared ad slowdown and multiple …
Caliber (Nasdaq: CWD) announced the launch of its PURE Pickleball & Padel real estate investment offering on its platform as the first to be tokenized, utilizing blockchain technology to improve transparency, investor experience, and liquidity. This initiative uses Chainlink's Automated Compliance Engine for investor verification and compliance. Th…
Cellectar Biosciences reported strong second quarter 2026 results, highlighted by initiation of site activation for the confirmatory Phase 3 trial of iopofosine I 131 in Waldenström Macroglobulinemia, planned NDA submission under FDA's Accelerated Approval Program in mid-2027, positive Phase 2b CLOVER WaM data, and ongoing Phase 1b trial enrollment…
Liminatus Pharma, a biopharmaceutical company, announced its stock was transferred to the Nasdaq Capital Market and that it received an extension until September 3, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The company intends to take necessary actions to comply while continuing its clinical development in cancer thera…
Pelthos Therapeutics announced its Q2 2026 financial results highlighting a 45% quarter-over-quarter increase in net product revenue for Zelsuvmi, reaching $15.4 million. The company has surpassed 25,000 patients prescribed since launching Zelsuvmi in July 2025 and expects continued growth. It secured a $50 million credit facility to support commer…
MKS (MKSI) sits at the intersection of secular AI build-out and legacy industrial cycles. Recent plant expansions in China and Malaysia and steady free cash flow position the company to capture AI-driven demand for advanced packaging, PCBs and wafer-level processes. At a market cap near $20.7B and a valuation that reflects cyclical variability rath…
With the US-Iran war continuing and supply cuts mounting, global oil inventories offer limited clarity on how long markets could be shielded from a prolonged disruption. Agencies and consultancies cite large headline stockpiles, but the volume that can actually be tapped is smaller and vulnerable, particularly for diesel and jet fuel. Key uncertain…
POET Technologies Inc. reported a 112% year-over-year revenue increase in Q2 2026, marking its sixth consecutive quarter of sequential growth. The net loss narrowed compared to prior quarters, bolstered by a substantial $400 million financing completed in May, enhancing the company's balance sheet and enabling manufacturing capacity expansion. POET…
Chicago Atlantic BDC, Inc., a NASDAQ-listed specialty finance company focusing on direct loans primarily to privately held middle-market companies in the cannabis sector, announced a quarterly cash dividend of $0.34 per share for Q3 2026. The dividend record date is September 25, 2026, with payment on October 9, 2026. The company emphasizes maximiz…
Victoria's Secret & Co. (NYSE: VSXY) announces its second quarter 2026 earnings release and invites investors and analysts to participate in a live webcast conference call scheduled for September 3, 2026. The company provides details about accessing the webcast and highlights its business segments, including Victoria's Secret, PINK, and Adore Me. A…
Parabilis Medicines reported progress in its clinical programs, especially zolucatetide—an investigational direct inhibitor targeting the β-catenin:TCF interaction in multiple Wnt/β-catenin-driven diseases. The company plans to initiate a Phase 3 registrational trial for desmoid tumors in early 2027. Parabilis also announced a major collaboration w…
LENSAR, Inc. reported its second quarter 2026 financial results, highlighting an 18% increase in total revenue and a 20% growth in recurring revenue compared to the same period last year. The company placed 10 new ALLY Robotic Cataract Laser Systems during the quarter, increasing the installed base to 445 systems. Net income turned positive at $3.5…
The Scotts Miracle-Gro Company is collaborating with America250 to bring the 'Our American Story' Airstream mobile studio to ScottsMiracle-Gro Field in Columbus, Ohio, as part of the nation's 250th anniversary celebrations. The initiative aims to collect oral and visual histories that highlight Ohio's cultural and historical influence in America. T…
Legence Corp. reported strong second quarter 2026 financial results with record revenues of $1.26 billion, a 111% increase year-over-year, driven by solid organic growth and the Bowers acquisition. Adjusted EBITDA more than doubled to $154.6 million. The company also reported record backlog and awarded contracts totaling $5.67 billion, a 105% incre…
ProQR Therapeutics reported positive Phase 1 target engagement data for AX-0810, marking the first clinical validation of its proprietary Axiomer RNA editing platform targeting NTCP modulation for cholestatic diseases. The company outlined a robust pipeline with upcoming clinical milestones including Phase 1 data for AX-0811, initiation of biliary …
Aebi Schmidt Group reported a 22% increase in adjusted EBITDA and a 16% growth in order intake for Q2 2026 compared to Q2 2025, alongside a 9% rise in net sales. The company attributes its improved profitability to operational improvements and an expanded market footprint, with strong performance in North America and Europe. Net income turned posit…
Tilray Brands' Montauk Brewing Company announced a partnership with Morning Brew Inc. to release The Morning Brew, a limited-edition light blonde ale. This collaboration enhances Montauk Brewing’s brand presence and leverages Morning Brew’s media influence, with plans for ongoing promotional activities leading up to the 2026 New York City Marathon.
